Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
CAR-T Cell Therapy Market: By Targeted Antigen, By Therapeutic Application, and Geography
CAR-T Cell Therapy Market: By Targeted Antigen, By Therapeutic Application, and Geography
CAR-T Cell Therapy Market size was valued at US$ 2.1 billion in 2023 and is poised to grow at a CAGR of 14.2% from 2024 to 2030. The global market provides a detailed overview of the market and that can be segmented by targeted antigen and therapeutic application. By targeted antigen, the market has been segmented into CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, and EGFRvlll. The CD 19 segment is likely to be the largest and fastest-growing segment in terms of targeted antigen. Based on therapeutic application, the market is segmented into leukemia, chronic lymphocytic leukemia, non-Hodgkin leukemia, multiple myeloma, pancreatic cancer, neuroblasts, breast cancer, and acute myeloid leukemia, hepatocellular carcinoma, and colorectal cancer. Among these, the non-Hodgkin leukemia segment is expected to have the fastest-growing market during the forecast period.
Study Period
2024-2030Base Year
2023CAGR
14.2%Largest Market
North AmericaFastest Growing Market
Asia-Pacific
CAR-T cell therapy solutions are receiving more approvals, the prevalence of obesity together with rising cancer case, growing demand for effective treatments for cancer, and huge steady investment activities by pharmaceutical companies' are some key factors fostering the market growth.
By region, the Asia Pacific market is expected to witness the highest market share during the forecast period since more international players are working together and signing contracts with local players to provide CAR-T cell therapies in this area. North America held significant market share during estimated period due to the region's availability of cutting-edge research institutions and laboratories, enhanced healthcare infrastructure, rising per capita income, early availability of licensed treatments, and these factors.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 2.1 billion |
|
Market CAGR |
14.2% |
|
By Targeted Antigen |
|
|
By Therapeutic Application |
|
|
By Region |
|
Download Free Sample Report
The CAR-T cell therapy market size was valued at US$ 2.1 billion in 2023 and is projected to grow at a CAGR of 14.2% from 2024 to 2030.
Biopolymer GmbH & Co KG (Germany), Merz GmbH & Co. KGaA (Germany), Lumenis (U.S.), Revance Therapeutics, Inc. (U.S), Speciality European Pharma (U.K.), Mentor Worldwide LLC (U.K.), Anika Therapeutics, Inc. (U.S.), Contura International A/S (Denmark), Cynosure, Inc. (U.S.), Fibrocell Science Inc. (U.S), Galderma S/A (Switzerland)
Asia-Pacific is the fastest-growing region for CAR-T cell therapy market
| 1.Executive Summary |
| 2.Global CAR-T Cell Therapy Market Introduction |
| 2.1.Global CAR-T Cell Therapy Market - Taxonomy |
| 2.2.Global CAR-T Cell Therapy Market - Definitions |
| 2.2.1. By Targeted Antigen |
| 2.2.2. By Therapeutic Application |
| 2.2.3. By Region |
| 3.Global CAR-T Cell Therapy Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global CAR-T Cell Therapy Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global CAR-T Cell Therapy Market By Targeted Antigen, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. CD 19 |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. CD 20 |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. GD2 |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. CD22 |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. CD30 |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. CD33 |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. HER1 |
| 5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. HER2 |
| 5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 5.9. Meso |
| 5.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.9.3. Market Opportunity Analysis |
| 5.10. EGFRvlll |
| 5.10.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.10.3. Market Opportunity Analysis |
| 6.Global CAR-T Cell Therapy Market By Therapeutic Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Leukemia |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Chronic Lymphocytic Leukemia |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Non Hodgkin Leukemia |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Multiple Myeloma |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Pancreatic Cancer |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Neuroblasta |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Breast Cancer |
| 6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 6.8. Acute Myeloid Leukemia |
| 6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.8.3. Market Opportunity Analysis |
| 6.9. Hepatocellular Carcinoma |
| 6.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.9.3. Market Opportunity Analysis |
| 6.10. Colorectal Cancer |
| 6.10.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.10.3. Market Opportunity Analysis |
| 7.Global CAR-T Cell Therapy Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America CAR-T Cell Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Targeted Antigen Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.CD 19 |
| 8.1.2.CD 20 |
| 8.1.3.GD2 |
| 8.1.4.CD22 |
| 8.1.5.CD30 |
| 8.1.6.CD33 |
| 8.1.7.HER1 |
| 8.1.8.HER2 |
| 8.1.9.Meso |
| 8.1.10.EGFRvlll |
| 8.2. Therapeutic Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Leukemia |
| 8.2.2.Chronic Lymphocytic Leukemia |
| 8.2.3.Non Hodgkin Leukemia |
| 8.2.4.Multiple Myeloma |
| 8.2.5.Pancreatic Cancer |
| 8.2.6.Neuroblasta |
| 8.2.7.Breast Cancer |
| 8.2.8.Acute Myeloid Leukemia |
| 8.2.9.Hepatocellular Carcinoma |
| 8.2.10.Colorectal Cancer |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe CAR-T Cell Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Targeted Antigen Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.CD 19 |
| 9.1.2.CD 20 |
| 9.1.3.GD2 |
| 9.1.4.CD22 |
| 9.1.5.CD30 |
| 9.1.6.CD33 |
| 9.1.7.HER1 |
| 9.1.8.HER2 |
| 9.1.9.Meso |
| 9.1.10.EGFRvlll |
| 9.2. Therapeutic Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Leukemia |
| 9.2.2.Chronic Lymphocytic Leukemia |
| 9.2.3.Non Hodgkin Leukemia |
| 9.2.4.Multiple Myeloma |
| 9.2.5.Pancreatic Cancer |
| 9.2.6.Neuroblasta |
| 9.2.7.Breast Cancer |
| 9.2.8.Acute Myeloid Leukemia |
| 9.2.9.Hepatocellular Carcinoma |
| 9.2.10.Colorectal Cancer |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) CAR-T Cell Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Targeted Antigen Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.CD 19 |
| 10.1.2.CD 20 |
| 10.1.3.GD2 |
| 10.1.4.CD22 |
| 10.1.5.CD30 |
| 10.1.6.CD33 |
| 10.1.7.HER1 |
| 10.1.8.HER2 |
| 10.1.9.Meso |
| 10.1.10.EGFRvlll |
| 10.2. Therapeutic Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Leukemia |
| 10.2.2.Chronic Lymphocytic Leukemia |
| 10.2.3.Non Hodgkin Leukemia |
| 10.2.4.Multiple Myeloma |
| 10.2.5.Pancreatic Cancer |
| 10.2.6.Neuroblasta |
| 10.2.7.Breast Cancer |
| 10.2.8.Acute Myeloid Leukemia |
| 10.2.9.Hepatocellular Carcinoma |
| 10.2.10.Colorectal Cancer |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) CAR-T Cell Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Targeted Antigen Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.CD 19 |
| 11.1.2.CD 20 |
| 11.1.3.GD2 |
| 11.1.4.CD22 |
| 11.1.5.CD30 |
| 11.1.6.CD33 |
| 11.1.7.HER1 |
| 11.1.8.HER2 |
| 11.1.9.Meso |
| 11.1.10.EGFRvlll |
| 11.2. Therapeutic Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Leukemia |
| 11.2.2.Chronic Lymphocytic Leukemia |
| 11.2.3.Non Hodgkin Leukemia |
| 11.2.4.Multiple Myeloma |
| 11.2.5.Pancreatic Cancer |
| 11.2.6.Neuroblasta |
| 11.2.7.Breast Cancer |
| 11.2.8.Acute Myeloid Leukemia |
| 11.2.9.Hepatocellular Carcinoma |
| 11.2.10.Colorectal Cancer |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America CAR-T Cell Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Targeted Antigen Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.CD 19 |
| 12.1.2.CD 20 |
| 12.1.3.GD2 |
| 12.1.4.CD22 |
| 12.1.5.CD30 |
| 12.1.6.CD33 |
| 12.1.7.HER1 |
| 12.1.8.HER2 |
| 12.1.9.Meso |
| 12.1.10.EGFRvlll |
| 12.2. Therapeutic Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Leukemia |
| 12.2.2.Chronic Lymphocytic Leukemia |
| 12.2.3.Non Hodgkin Leukemia |
| 12.2.4.Multiple Myeloma |
| 12.2.5.Pancreatic Cancer |
| 12.2.6.Neuroblasta |
| 12.2.7.Breast Cancer |
| 12.2.8.Acute Myeloid Leukemia |
| 12.2.9.Hepatocellular Carcinoma |
| 12.2.10.Colorectal Cancer |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Biopolymer GmbH & Co KG (Germany) |
| 13.2.2.Merz GmbH & Co. KGaA (Germany) |
| 13.2.3.Lumenis (U.S.) |
| 13.2.4.Revance Therapeutics, Inc. (U.S) |
| 13.2.5.Speciality European Pharma (U.K.) |
| 13.2.6.Mentor Worldwide LLC (U.K.) |
| 13.2.7.Anika Therapeutics, Inc. (U.S.) |
| 13.2.8.Contura International A/S (Denmark) |
| 13.2.9.Cynosure, Inc. (U.S.) |
| 13.2.10.Fibrocell Science Inc. (U.S) |
| 13.2.11.Galderma S/A (Switzerland) |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.